Recent studies have established midbrain CD163+ macrophages as key players in MDD pathophysiology, opening new avenues for developing anti-inflammatory approaches that synergize with conventional antidepressants to enhance therapeutic efficacy (Mendez-Victoriano et al., 2024). The gene discussed is CD163; the disease is major depressive disorder.